Table 1.
PRAME mRNA expression in CML samples from patients at different stage of disease
| Pt | Disease stage | Treatment | Copy number of PRAME, average ± SD (range) | Level of PRAME mRNA expression |
|||
|---|---|---|---|---|---|---|---|
| N < 0.1 | 0.1 < N < 1 | 1 < N < 10 | N > 10 | ||||
| 20 | Dx | None | 3.46 ± 4.34 (0-18.3) | 1 (5%) | 4 (20%) | 14 (70%) | 1 (5%) |
| 14 | CP | < 60 mo IFN-α | 11.17 ± 22.79 (0-83.12) | 1 (7%) | 4 (29%) | 6 (43%) | 3 (21%) |
| 6 | CP | > 60 mo IFN-α | 24.31 ± 46.60 (0.4-118.8) | 0 | 1 (16%) | 3 (50%) | 2 (34%) |
| 8 | CP | < 60 mo IM | 17.85 ± 25.80 (0-65.83) | 1 (12%) | 3 (38%) | 1 (12%) | 3 (38%) |
| 10 | BC | IFN-α/IM | 95.97 ± 163.49 (1.19-515.98) | 0 | 0 | 3 (30%) | 7 (70%) |
Pt indicates patient number; N, normalized mRNA copy number (mRNA copy PRAME/Gusb*104); Dx, CML at diagnosis; CP, CML in chronic phase; BC, CML in blastic phase; IFN-α, interferon-α; and IM, imatinib (STI-571).